mitiglinide (Glufast) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mitiglinide is a drug for the treatment of type 2 diabetes.   Wikipedia

Chemistry

  • SMILES: OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc3ccccc3
  • InChIKey: WPGGHFDDFPHPOB-BBWFWOEESA-N
  • Mol. Mass: 315.41
  • ALogP: 2.97
  • ChEMBL Molecule:
    mitiglinide  
More Chemistry

Pharmacology

Alternative names

2-benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate | 2h-isoindole-2-butanoic acid, octahydro-gamma-oxo-alpha-(phenylmethyl)-, calcium salt, (2(s)-cis)- | calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate | insulin secretagogue | kad 1229 | kad-1229 | mitiglinide | miti-glinide | mitiglinide calcium | mitiglinide calcium dihydrate | mitiglinide calcium hydrate | s21403 | s 21403

Organizations (27)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 4)

Masked Hypertension (Phase 4)

Obesity (Phase 4)

Overweight (Phase 4)

Pharmacokinetics (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue